#leusm
LightNews LightNews
onclive.bsky.social
BREAKING 🚨: @fda.gov Approves Ziftomenib for NPM1+ R/R Acute Myeloid Leukemia

Learn more about the approval here 📰: onclive.com/view/fda-app...

#leusm #oncology #FDAapproved
FDA Approves Ziftomenib for NPM1+ R/R Acute Myeloid Leukemia | OncLive
Ziftomenib has received FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation.
onclive.com
November 13, 2025 at 3:37 PM
vjhemonc.bsky.social
In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England.

Watch here:

👉 buff.ly/FZdouqO 👈

#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
November 11, 2025 at 6:03 PM
vjhemonc.bsky.social
🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies.

Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei.

Watch now: 👉 buff.ly/VJJUbmz

#AMLsm #Leusm #Leukemia
November 11, 2025 at 10:01 AM
onclive.bsky.social
Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management #leusm #oncology www.onclive.com/view/pharmac...
Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management | OncLive
Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.
www.onclive.com
November 10, 2025 at 6:09 PM
oncologynurseadv.bsky.social
MRD-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk #CLL. Published in @bloodjournals.hematology.org and @rarediseaseadvisor.bsky.social.

https://bit.ly/4hSzzJ9

#leusm #lymsm
MRD-Guided Anti-CD20 Retreatment May Delay CLL Relapse - Oncology Nurse Advisor
Time to next treatment ranged from 0 months to 15.8 years, with a median of 2.3 years.
bit.ly
November 9, 2025 at 6:44 PM
vjhemonc.bsky.social
🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:

👉 buff.ly/BKMPQGT 👈

#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
November 8, 2025 at 2:01 PM
lymphomahub.bsky.social
Francesc Bosch discussed factors influencing fixed-duration BTKi + BCL-2i treatment selection for patients with CLL.

Listen here: https://loom.ly/rOxk8hM

#leusm #lymsm #MedNews #MedEd
November 7, 2025 at 3:07 PM
lymphomahub.bsky.social
Francesc Bosch discussed factors influencing the use of fixed-duration therapy for patients with CLL.

Watch the full video here: https://loom.ly/29aw1Zs

#leusm #lymsm #MedNews #MedEd
November 6, 2025 at 5:30 PM
onclive.bsky.social
FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid #Leukemia #leusm #oncology

www.onclive.com/view/fda-gra...
FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid Leukemia | OncLive
The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.
www.onclive.com
November 5, 2025 at 4:37 PM
vjhemonc.bsky.social
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉

We recently had the pleasure of speaking to Helen Parry to find out more about the study:

🎥 buff.ly/j1K0VV8

#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
November 5, 2025 at 1:19 PM
vjhemonc.bsky.social
🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:

👉 buff.ly/paPH5vx 👈

#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
November 4, 2025 at 9:29 AM
vjhemonc.bsky.social
In an interview from #iwAL25, Tara Lin discusses the possibility of tailoring treatment for secondary AML dependent on mutational profile, highlighting the heterogeneity of this disease.

Watch here:

👉 buff.ly/HbJTfmF 👈

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky
November 2, 2025 at 4:01 PM
vjhemonc.bsky.social
It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.

Watch the interview here:

🎥 buff.ly/sZGLLe2

#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
November 1, 2025 at 2:01 PM
lymphomahub.bsky.social
What factors influence BTKi + BCL-2i treatment selection for patients with CLL? The Lymphoma Hub was pleased to speak to Francesc Bosch, University Hospital Vall d’Hebron, about the use of fixed-duration therapy in CLL.

Watch here: https://loom.ly/29aw1Zs

#leusm #lymsm #MedNews #MedEd
October 31, 2025 at 12:04 PM
lymphomahub.bsky.social
Francesc Bosch, University Hospital Vall d’Hebron, discussed factors influencing BTKi + BCL-2i treatment selection for patients with CLL.

Watch here: https://loom.ly/29aw1Zs

#leusm #lymsm #MedNews #MedEd
October 29, 2025 at 11:02 PM
talhabadarmd.bsky.social
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
October 29, 2025 at 9:25 PM
vjhemonc.bsky.social
#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:

🎥 buff.ly/s2zXiCa

#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
October 29, 2025 at 5:42 PM
talhabadarmd.bsky.social
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML ashpublications.org/bloodadvances/… #Agile_study:mOSOS 24 mo.#cross-trialal comparison; VIALE-A trial mOS IDH2-m AML ( 27.5 vs 13 mo) & IDH1-m AML (median 10.2 vs 2.2 mo#leusms#AMLML
October 29, 2025 at 11:24 AM
hematologyadvisor.bsky.social
Among a heavily pretreated, older adult population of patients with R/R NPM1m #AML, revumenib was associated with a clinically meaningful response while retaining a safety profile consistent with previous findings. Published in @bloodjournals.hematology.org.

https://bit.ly/4ode7AQ

#leusm
Revumenib Shows Promise in Treating NPM1-Mutated Relapsed/Refractory AML
Researchers determined revumenib showed promising efficacy in patients with R/R NPM1m AML.
bit.ly
October 28, 2025 at 6:20 PM
vjhemonc.bsky.social
How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸

Jacob Soumerai discussed this in a recent interview:

🎥 buff.ly/6qCplqB

#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky
October 28, 2025 at 4:48 PM
hematologyadvisor.bsky.social
TFR is a feasible target for patients with #CML living in low- and middle-income countries, according to research presented at #ESMO25.

https://bit.ly/4727w6m

#leusm
Patients With CML Living in LMICs May Reach High TFR Rates - Hematology Advisor
Researchers evaluated long-term outcomes among patients with CML living in LMICs who received imatinib through financial assistance from the Max Foundation.
bit.ly
October 25, 2025 at 8:53 PM
hematologyadvisor.bsky.social
Many patients with #CLL/#SLL who were intolerant of ibrutinib and/or acalabrutinib were able to tolerate and benefit from zanubrutinib. Published in @bloodjournals.hematology.org.

https://bit.ly/4o0q7Wd

#leusm
Zanubrutinib May Benefit CLL/SLL Patients Intolerant of Other BTK Inhibitors
Researchers determined zanubrutinib may be effective for patients with CLL/SLL who were intolerant to other BTK inhibitors.
bit.ly
October 24, 2025 at 8:45 PM
onclive.bsky.social
BREAKING 🚨: @fda.gov Approves Revumenib for R/R NMP1-Mutant AML

Learn more here: 🔗 onclive.com/view/fda-app...

#leusm #oncology #FDAapproved
October 24, 2025 at 5:33 PM
vjhemonc.bsky.social
🎥 Moritz Fürstenau comments on the optimal duration of time-limited BTK inhibitor plus BCL2 inhibitor combination therapy in CLL:

👉 buff.ly/BiuqDZd 👈

#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
October 24, 2025 at 1:04 PM
ash.hematology.org
Sharpen your diagnostic accuracy and personalize therapy decisions for your patients with acute lymphoblastic leukemia and lineage ambiguous leukemia.

ASH connects you with experts in precision hematology. Don't miss it! https://ow.ly/uqyX50Xf4NZ

#Hemesky #Medsky #Leusm #PrecisionHeme #Lymsm
October 23, 2025 at 11:55 AM